Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for ovarian cancer: targeted drug T-DXd tested after standard treatments fail

NCT ID NCT07340164

Recruiting now Disease control Sponsor: Yonsei University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests whether trastuzumab deruxtecan (T-DXd), a targeted antibody-drug conjugate, works better than standard chemotherapy for recurrent ovarian cancer that has stopped responding to PARP inhibitors. About 116 participants whose tumors express the HER2 protein will be randomly assigned to receive T-DXd or chemotherapy. The study aims to find a new effective treatment for this hard-to-treat cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
trastuzumab deruxtecan (T-DXd, Enhertu)
What this could lead to
If successful, this could offer a new treatment option for people with recurrent ovarian cancer who have stopped responding to PARP inhibitors.
What could go wrong
This is a Phase 2 trial with only 116 participants, so results are preliminary. The drug may not work better than standard chemotherapy and could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube endometrioid adenocarcinoma fallopian tube serous adenocarcinoma ovarian cancer ovarian carcinoma ovarian endometrioid adenocarcinoma ovarian serous adenocarcinoma primary peritoneal carcinoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER OVARIAN CANCER (OVCA) OVARIAN CANCER METASTATIC RECURRENT OVARIAN CARCINOMA, RECURRENT

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Yonsei University Health System, Severance Hospital

    RECRUITING

    Seoul, Seoul, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.